Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.52 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 4/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | TP53 | P04637 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6985740 | 0.83 | MTNR1A (0.55) | CA2MTNR1AMTNR1BCYP2A6KEAP1 | |
| SCHEMBL2093816 | 0.81 | CA2 (0.55) | CA2MTNR1AMTNR1BCYP2A6KEAP1 | |
| SCHEMBL6003503 | 0.81 | MTNR1A (0.60) | CA2MTNR1AMTNR1BCYP2A6KEAP1 | |
| SCHEMBL2114297 | 0.81 | CA2 (0.55) | CA2MTNR1AMTNR1BCYP2A6KEAP1 | |
| SCHEMBL8274633 | 0.81 | CA2 (0.55) | CA2MTNR1AMTNR1BCYP2A6KEAP1 | |
| SCHEMBL4605763 | 0.81 | CYP2A6 (0.64) | CA2MTNR1AMTNR1BCYP2A6KEAP1 | |
| SCHEMBL4418009 | 0.79 | CYP2A6 (0.71) | CA2CYP2A6KEAP1NFE2L2MAPT | |
| SCHEMBL27628031 | 0.79 | MTNR1A (0.57) | CA2MTNR1AMTNR1BCYP2A6KEAP1 | |
| SCHEMBL8586113 | 0.79 | MTNR1A (0.57) | CA2MTNR1AMTNR1BCYP2A6MAPT | |
| SCHEMBL8435339 | 0.79 | MTNR1A (0.61) | CA2MTNR1AMTNR1BCYP2A6MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025122501-A1 | BENZOTHIOPHENE-3-YL- AND BENZOSELENOPHENE-3-YL (BICLYCLIC HETEROARYL) MALEMIDES AS GSK-3 INHIBITORS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2025-06-12 | — | — | WO | disclosed |
| EP-1140934-B1 | BENZISOXAZOLES AND PHENONES AS ALPHA-2-ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2003-10-08 | — | — | EP | disclosed |
| US-6576640-B1 | Rapidly penetration into central nervous system; treating noradrenaline deficiency; depression, Parkinson's disease | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-06-10 | — | — | US | disclosed |
| EP-1119571-B1 | TRICYCLIC DELTA3-PIPERIDINES AS ALPHA2-ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2003-02-19 | — | — | EP | disclosed |
| US-6495555-B1 | CENTRAL ALPHA2-ADRENOCEPTOR ANTAGONISTS; DEPRESSION; PARKINSON'S DISEASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-12-17 | — | — | US | disclosed |
| EP-1140934-A1 | BENZISOXAZOLES AND PHENONES AS $g(a) 2?-ANTAGONISTS | Janssen Pharmaceutica N.V. (BE) | 2001-10-10 | — | — | EP | disclosed |
| EP-1119571-A2 | TRICYCLIC DELTA3-PIPERIDINES AS ALPHA2-ANTAGONISTS | Janssen Pharmaceutica N.V. (BE) | 2001-08-01 | — | — | EP | disclosed |
| WO-2000037466-A1 | BENZISOXAZOLES AND PHENONES AS α2-ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-06-29 | — | — | WO | disclosed |
| WO-2000020421-A2 | TRICYCLIC Δ3-PIPERIDINES AS α2-ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-04-13 | — | — | WO | disclosed |